Daratumumab up for accelerated assessment in EU
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article5717140.ece/ALTERNATES/schema-16_9/Genmab_logo_silver_on_green.jpg)
Genmab’s important cancer treatment daratumumab continue to make strides toward the market place and late last week, it was offered a shortcut to the European markets.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
New advance for Genmab's blockbuster in the making
For abonnenter
Genmab wins Priority Review for potential blockbuster
For abonnenter
New daratumumab data confirm huge potential
For abonnenter